Dr Greg van Wyk, CEO, Noxopharm Ltd 00:00:00

Share On Facebook Share On Twitter

Noxopharm Limited (ASX:NOX) CEO & CMO Dr Greg van Wyk talks about interim data at 24 weeks for the company's DARRT-1 clinical trial for prostate cancer.

Recent Videos